<DOC>
	<DOCNO>NCT01703988</DOCNO>
	<brief_summary>This study test safety , tolerability , pharmacokinetics escalate dos nusinersen ( ISIS 396443 ) administer spinal fluid either two three time duration trial , participant spinal muscular atrophy ( SMA ) . Four dose level evaluate sequentially . Each dose level study cohort approximately 8 participant , participant receive active drug .</brief_summary>
	<brief_title>An Open-label Safety , Tolerability Dose-Range Finding Study Multiple Doses Nusinersen ( ISIS 396443 ) Participants With Spinal Muscular Atrophy</brief_title>
	<detailed_description>This study conduct protocol register Ionis Pharmaceuticals , Inc . In August 2016 , sponsorship trial transfer Biogen .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Key Genetic documentation 5q SMA ( homozygous gene deletion mutation ) Clinical sign attributable SMA Able complete study procedure , measurement , visit parent/patient adequately supportive psychosocial circumstance , opinion Investigator Estimated life expectancy &gt; 2 year Screening Meets ageappropriate institutional criterion use anesthesia/sedation , use plan study procedure Key Respiratory insufficiency define medical necessity invasive noninvasive ventilation 24hour period Medical necessity gastric feed tube , majority feed give route , assess Investigator Previous scoliosis surgery would interfere lumbar puncture injection procedure Hospitalization surgery ( e.g . scoliosis surgery ) pulmonary event within 2 month screen plan duration study Presence untreated inadequately treat active infection require systemic antiviral antimicrobial therapy time screen period History brain spinal cord disease would interfere lumbar puncture procedures cerebrospinal fluid ( CSF ) circulation Presence implant shunt drainage CSF implanted central nervous system catheter History bacterial meningitis Dosing ISIS 396443 clinical study ISIS 396443CS1 Cohorts 2 , 3 , 4 Dosing ISIS 396443 clinical study ISIS 396443CS10 Clinically significant abnormality hematology clinical chemistry parameter electrocardiogram ( ECG ) Screening visit , assess Site Investigator would render subject unsuitable inclusion Treatment investigational drug , biological agent , device within 1month Screening 5 halflives study agent , whichever longer . Treatment valproate hydroxyurea within 3months screen . Any history gene therapy cell transplantation Ongoing medical condition would interfere conduct assessment study . Examples medical disability ( e.g . waste cachexia , severe anemia ) would interfere assessment safety would compromise ability patient undergo study procedure . NOTE : Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>SMA</keyword>
	<keyword>SMN</keyword>
	<keyword>SMNRx</keyword>
	<keyword>ISIS-SMNRx</keyword>
	<keyword>ISIS 396443</keyword>
</DOC>